Sherida H. Jin-Woei

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Haematology

Published: March 31, 2026

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.

Journal: The Lancet. Haematology

Published: December 18, 2025

Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.

Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.

Journal: Blood cancer journal

Published: November 01, 2024

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Journal: The Lancet. Haematology

Published: October 24, 2024

Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands.

Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands.

Journal: EJHaem

Published: October 09, 2024

International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma.

International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 31, 2024

Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.

Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.

Journal: Blood advances

Published: May 20, 2024

Improving quality of life in cutaneous lymphoma patients.

Improving quality of life in cutaneous lymphoma patients.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 17, 2024

Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.

Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 22, 2024

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Journal: Blood neoplasia

Published: April 11, 2024

Sulfasalazine-Induced Epstein-Barr Virus-Positive Mucocutaneous Ulcer.

Sulfasalazine-Induced Epstein-Barr Virus-Positive Mucocutaneous Ulcer.

Journal: Case reports in hematology

Published: March 29, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026